This individual is a guest contributor. MEI is not able to assist with contact requests.
Dave Burrows is Director of APMGlobal Health. He has worked on HIV and drug issues since 1987. In Sydney Australia from 1987 to 1994, Dave first wrote and edited publications on drugs and HIV for a variety of audiences from medical professionals to alcohol and other drug treatment workers to adolescents and the general public, then managed a non-government, community-based agency (NUAA) specifically targeting people who inject drugs (PWID) with HIV prevention, education, care and support services. He joined the national peak body of Australian AIDS service organizations (AFAO) in 1994, and soon became Deputy Director, conducting national policy work and supervising the organization’s Policy, Publications and Administration teams.
Since 1996, Dave has worked as a consultant on HIV/AIDS and drug use issues in 62 countries. He has assisted all relevant UN and global organizations, several bilateral government aid agencies and many international non-government organizations in a wide range of tasks including program design and managing program implementation, negotiation with key stakeholders, evaluation and documentation. In recent years, Dave has increasingly worked on broader issues related to HIV/AIDS than those affecting drug users, and has designed programs targeting other groups such as medical professionals, youth, people living with HIV, men who have sex with men and commercial sex workers. He was a HIV Expert for Rounds 4-6 on the Technical Review Panel of the Global Fund to Fight AIDS, TB and Malaria.
Comparing Harm Reduction Advocacy Approaches in the Middle East, Central Asia, and Southeast Asia
For more than three decades, harm reduction initiatives for people who inject drugs (PWID) have focused on preventing the spread of HIV. The objectives of harm reduction activities have gradually expanded to include reducing the number of PWID through education programs, stopping the spread of hepatitis C and other infections, and preventing overdoses. However, the single greatest rationale for introducing or scaling up harm reduction remains HIV prevention and (to a lesser extent) treatment, care, and support for PWID living with HIV.
